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Abstract 
Introduction and aim. In a randomised trial investigating the effects of regular 
use of health-related quality of life (HRQOL) in oncology practice, we previously 
reported an improvement in communication (objective analysis of recorded 
encounters) and patient well-being. The secondary aims of the trial were to 
measure any impact on patient satisfaction and patients‟ perspectives on 
continuity and co-ordination of their care.  
Methods. In a prospective trial involving 28 oncologists, 286 cancer patients 
were randomized to: 1) Intervention arm: regular touch-screen completion of 
HRQOL with feedback to physicians; 2) Attention-control arm: completion of 
HRQOL without feedback; 3) Control arm: no HRQOL assessment. Secondary 
outcomes were patients‟ experience of continuity of care (Medical Care 
Questionnaire) including “Communication” “Coordination” and “Preferences to 
see usual doctor” subscales, patients‟ satisfaction, and patients‟ and physicians‟ 
evaluation of the intervention. Analysis employed mixed-effects modelling, 
multiple regression and descriptive statistics.  
Results. Patients in the intervention arm rated their continuity of care as better 
than the control group for “Communication” subscale (p=.03). No significant 
effects were found for “Coordination” or “Preferences to see usual doctor”. 
Patients‟ evaluation of the intervention was positive. More patients in the 
intervention group rated the HRQOL assessment as useful compared to the 
attention-control group (86% vs 29%), and reported their doctors considered daily 
activities, emotions and quality of life. 
Conclusion. Regular use of HRQOL measures in oncology practice brought 
changes to doctor-patient communication of sufficient magnitude and importance 
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to be reported by patients. HRQOL data may improve care through facilitating 
rapport and building interpersonal relationships. 
 
Key words: Patient-reported outcomes, continuity of care, communication, 
health-related quality of life, oncology
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INTRODUCTION 
Patient-reported outcome questionnaires (PROs) are self-completed validated 
questionnaires designed to assess health status or health-related quality of life 
(HRQOL)1,2. They capture patients‟ experiences of symptoms and impact of 
disease on functioning, and can support physicians in clinical practice to monitor 
patient problems and facilitate patient-centred care3-5. 
 
Systematic reviews evaluating the impact of PROs on clinical practice 
demonstrated a positive effect on patient-physician communication, but less 
consistent improvement in patient health outcomes or satisfaction6-10.  
 
We conducted a randomised controlled trial (RCT) of regular touch-screen 
computer collection and feedback of HRQOL data to oncologists, confirming a 
positive effect on physician-patient communication (measured objectively from 
audio-recorded encounters) and patient well-being11. Secondary aims were to 
measure the impact of the intervention on patient satisfaction and perceptions of 
continuity and co-ordination of care. Secondary outcomes were expected to 
provide insight into possible mechanisms underlying the observed changes in 
patient well-being.  
 
Measures of patient satisfaction in oncology are subject to ceiling effects, as 
patients do not rate their medical team negatively12. We found high general 
patient satisfaction in the pre-trial pilot and decided to investigate specific aspects 
of care13. Assessment of continuity and co-ordination of care was chosen, as the 
research was conducted in a tertiary cancer centre with care delivered by teams 
of physicians (5-8 doctors), and patients were often seen by different physicians. 
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Continuity of medical care was defined as „the extent to which health services are 
received as a coordinated and uninterrupted succession of events consistent with 
the patient‟s medical needs”14. Continuity of clinical data and information were 
key components of care coordination15. HRQOL measurement can be viewed as 
a tool that ensures continuous flow of subjective symptoms/functioning 
information from the patient to the medical team16.  
 
This article reports secondary trial outcomes (continuity of care and patient 
satisfaction) and patients‟ and doctors‟ evaluation of the intervention. We 
hypothesize that the use of patient-reported HRQOL data will improve 
“coordination” of patient information between doctors and improve 
“communication” about non-medical problems. These effects may result in less 
strong “patient preferences” to see usual doctor, as all doctors have similar 
patient-reported information. We expected patients to report high general 
satisfaction with care.   
 
METHODS 
Trial methodology has been described 11. Brief key information is provided. 
 
Participants 
Patients attending the Medical Oncology Clinic at St James Hospital, Leeds, UK 
were eligible if they were commencing treatment, expected to attend at least 3-
times, fluent in English and not exhibiting psychopathology. All medical 
oncologists and oncologists-in-training were invited. The study was approved by 
the institutional ethical committee. Patients and clinicians provided written 
informed consent.  
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Design 
A 3-arm RCT with repeated measures. Patients were randomised to: 1) 
Intervention arm (touch-screen HRQOL questionnaire completion and feedback 
of results to physicians); 2) Attention-Control arm (touch-screen HRQOL 
questionnaire completion, without feedback); and 3) Control arm (no 
measurement of HRQOL in clinic). The random assignment was unbalanced 
2:1:1 and stratified by cancer site. Randomisation was carried out by telephone 
by the research office.  
 
Secondary patient outcomes were measured using paper questionnaires (given 
to patients to complete at home and return by post) at four time-points: baseline, 
after 3 visits, 4 and 6 months. 
 
Experimental intervention 
Intervention questionnaires were EORTC QLQ-C3017 and Hospital Anxiety and 
Depression Scale18, completed on touch-screen computers in clinics. Graphic 
printouts of results were provided to physicians11. 
 
Patient Outcome Measures 
Continuity and coordination of care. At the time of trial setup we could not find 
a suitable measure of patient perceptions of continuity/coordination of care 
delivered by multi-disciplinary teams. We developed and validated a new 
instrument-Medical Care Questionnaire (MCQ) in 677 cancer patients16. It has 15 
items grouped in 3 subscales with good reliability: “Communication” (patient feels 
comfortable to discuss non-medical issues, α=0.69), “Coordination” (patient 
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perceptions of continuity/coordination of medical information, α=0.84) and 
“Patient Preferences” (to see the usual doctor, α=0.75) (Appendix 1). Scores are 
transformed to a 0-100 scale, high “Communication” and “Coordination” scores 
indicate good communication/coordination; high “Preferences” scores indicate 
strong preference for usual doctor.  
 
Satisfaction with care was measured by two questions “How would you rate the 
overall quality of your medical care?” (very poor, poor, fair, good, very good, 
excellent), and “How well do doctors in this clinic meet your expectations?” (not at 
all, not so well, to some extent, very well, extremely well).   
 
Patients’ and physicians’ evaluation of the intervention. Descriptive 
information was collected using end-of-study questionnaires for patients and 
doctors. Topics included: 1) patients‟ experience with the touch-screen 
questionnaires; 2) content/relevance of the questionnaires; 3) usefulness of the 
intervention (willingness to use in routine care) (Appendix 2). End-of-study 
questionnaires were sent to patients in the intervention and attention-control arms 
and to doctors working in the centre at the trial closure.  
 
Other measures 
K-index is as an objective measure of continuity of care, defined as:  
K-index = (Number of visits – Number of doctors) / (Number of visits – 1)14,19.  
K-index=1, if patients see one doctor over time, and 0, if patients see different 
doctors each visit. 
 
Statistical Analysis 
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Continuity and coordination of care. The control and attention-control arms 
were each compared with the intervention arm using mixed-effects models for 
each MCQ subscale. Each model included the MCQ subscale change score as 
the outcome variable, fixed effects were baseline MCQ subscale score, study 
arm, time, and potential predictor covariates. Predictors were identified using 
univariate linear regression, with the change in MCQ subscales after three visits 
as the outcome variable and each covariate as the single explanatory variable. 
The covariates considered were patient age, gender, diagnosis, performance 
status, disease extent, treatment response, doctor gender (percentage females), 
doctor seniority (percentage consultants) and K-Index. Covariates meeting the 
inclusion criterion (p < .1) were entered in the mixed-effects model. 
 
Time was entered in the model as a continuous variable (in days). The main 
effect of time was assessed as a fixed effect, and nested as a random effect 
within patients to allow the relationship between time and outcome to vary 
between individuals. Mixed modelling assumes missing data is missing-at-
random. The relationship between time of dropout and MCQ scores was 
investigated by arm in order to aid the interpretation of results under this 
assumption and check the robustness of the results to deviations from this 
assumption. 
 
Satisfaction with care, patients’ and physicians’ evaluation questionnaires 
were analysed descriptively.  
 
All analyses were on an intention to treat. Significance level was set at 5% for 
pre-planned analyses. The analyses were performed with SPSS Windows 
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Version 16.0 (SPSS Inc,Chicago, IL) and SAS version 9.1.3. (SAS Institute Inc, 
Cary,NC). 
 
RESULTS 
The trial recruited between January 2000 and July 2001. All 28 medical 
oncologists working in the unit participated: 17 were male (reflecting the male-
female balance in the medical profession in UK); median age 33.5, range 26-51 
years; 22 oncologists-in-training and 6 consultants.  
 
Patients‟ progress through the study is presented in Figure 1. From 419 eligible 
patients, 286 patients (68%) consented. The 6 month attrition rate was 35% in 
the intervention arm, 46% in the attention-control and 33% in the control arm, 
predominantly due to death (58% of drop-out cases), 87% of patients remaining 
on study completed the MCQ measure each time.  
 
End of study questionnaires were returned by 91% of patients (119/131 patients 
in intervention/attention-control arms finishing the study); 22 oncologists, working 
at the centre at trial closure, completed the questionnaire.  
 
Table 1 represents patient characteristics of the sample analysed for secondary 
outcomes, which were not different from those analysed for primary outcomes13.  
 
Continuity and coordination of care. The results of the mixed-effects models 
for MCQ subscales change scores are presented in Table 2 and Figure 2.  
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Patients in the intervention group rated their “Communication” with doctors 
significantly better than the control group (p=.03), but not different from the 
attention-control group (p =.16). Investigating the MCQ scores in relation to the 
timing of dropout indicated that this is likely to be a conservative estimate. 
Patients in the intervention group dropped out when their scores were favourable, 
whereas patients in the attention-control/control groups dropped out when their 
scores were poor. The mixed-effects model assuming data is missing-at-random 
would underestimate the difference between the groups. The control group 
showed a decline in scores to month 4 followed by improvement by month 6 
(Figure 2A). This improvement can be partially explained by attrition of patients 
with poor scores. Patient scores were associated with baseline MCQ 
“Communication” score (p<.0001). 
 
No significant arm effect was found for “Coordination” and “Preferences” 
subscales, where the change scores were dependent on baseline scores and K-
Index.  
 
Satisfaction with care. Between 79% and 89% of patients regardless of study 
arm rated their quality of care as “very good”/“excellent” (Figure 3). Between 89% 
and 95% of patients felt the doctors met their expectations (details not shown). 
 
Patients’ and physicians’ evaluation of the intervention.  
Patients did not feel participation in the study made their clinic visits more difficult 
(98%, n=119). In the intervention arm (n=85) 86% patients perceived the 
questionnaires were useful to tell the doctors how they were feeling, compared to 
29% of patients in the attention-control group (no feedback, n=34). 92% of 
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patients wanted to use the touch-screen intervention in routine care, 76% wanted 
the scores included in medical records. More patients in the intervention group 
than the attention-control felt the doctors considered their daily activities (65% vs 
53%), emotions (87% vs 71%) and quality of life (90% vs 74%) when treating 
them.  
 
From the 22 doctors responding to the end-of-study questionnaires 21 used 
HRQOL data “sometimes/often”, 12 made management changes, 15 were willing 
to use the data in routine care, 4 felt the study interfered with their clinical work 
“sometimes/often”. Reasons for not using the data were: forgot (12/22), no time 
(8/22), knew the patient (10/22), data irrelevant to patients‟ problems (5/22). 
 
DISCUSSION 
This pre-planned analysis examined the effects of regular use of HRQOL data in 
oncology practice on patients‟ perceptions of continuity and satisfaction with care. 
Patients reported improved communication with doctors, particularly aspects of 
building rapport and better inter-personal relationship, making it easier to discuss 
emotional/personal issues. The end-of-study questionnaire showed that more 
patients in the intervention than the attention-control group reported HRQOL data 
helped them to talk to the doctors, and felt the doctors considered daily activities, 
emotions and quality of life. These results support primary outcomes results from 
audio-recorded doctor-patient communications, showing increased discussion of 
symptoms, emotional and physical functioning11. Similar impact on 
communication was found in other trials12,20-21. Our findings suggest a 
mechanism through which improved doctor-patient communication may lead to 
better patient well-being. The HRQOL data helped to focus the consultation on 
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topics important to the patient and facilitated discussion of non-medical issues. 
This impact was sufficiently large to be noticed by patients and might be 
expected to contribute to better emotional well-being, as observed in the trial11.  
 
Patients expressed strong preferences to see their regular doctor, which was not 
influenced by the intervention. Similarly, the strongest predictor of “Coordination” 
of care was K-index (seeing different doctors) and the intervention did not 
overcome this negative effect.  
 
Limitation of this study is the use of a new instrument of patients‟ perceptions of 
continuity/coordination of care, making comparisons with other studies difficult. 
However, measuring general satisfaction again demonstrated ceiling effects and 
was not useful for comparison purposes 12,20-23.  
 
Non-participant rate (>30%) suggests this intervention may not be suitable for all 
patients, but this figure is similar to other studies with frequent data collection12.  
Significant attrition can be expected in advanced cancer, but the unbalanced 
attrition (46% in attention-control arm vs 33-35% in control and intervention arms) 
may influence results. We investigated possible effects of data not missing-at-
random and found a trend towards underestimating arm differences, but not 
influencing the direction of results. Bias cannot be completely excluded, as the 
sample size does not allow more complex modelling for missing data. 
 
In conclusion, this pre-planned analysis of secondary outcomes supports findings 
from the primary process of care outcomes showing positive effect of HRQOL 
data on physician-patient communication specifically focusing on continuity of 
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information, facilitating rapport and interpersonal relationships. Future work 
should target these mechanisms when implementing and training staff to use 
HRQOL data.   
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Figure 1 – Patient Progress through the study (CONSORT diagram) 
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Figure 2 – Change in Perceived Continuity of Care (Score at each time point minus 
score at baseline) by Study Arm over Time 
A. MCQ Communication subscale 
B. MCQ Coordination subscale 
C. MCQ Preferences subscale 
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Figure 3 – Proportion of Patient Ratings of Quality of Care by Study Arm over Time  
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Table 1 –Characteristics of Patients with Available MCQ data at Baseline 
 
   
Patient Group at Baseline 
 Intervention 
n = 129 
Attention 
Control 
n = 62 
Control 
n = 67 
Total 
n = 258 
Characteristic Mean SD Mean SD Mean SD Mean SD 
         
MCQ Baseline Scores         
    Communication  67.5 16.93 65.3 19.06 68.5 15.57 67.2 17.10 
              
    Preferences  65.5 26.32 66.8 23.68 61.6 25.94 64.8 25.59 
              
    Coordination  63.5 20.38 61.8 19.48 61.5 21.80 62.6 20.49 
              
Age, years 54.8 12.90 55.2 11.79 54.9 11.76 54.9 12.3 
         
 n % n % n % n % 
         
Sex         
    Female 97 75 46 74 51 76 194 75 
    Male 32 25 16 26 16 24 64 25 
Diagnosis         
    Breast cancer 26 20 11 18 11 16 48 19 
    Gynaecologic cancer 42 33 22 35 24 36 88 34 
    Renal cancer 21 16 9 15 11 16 41 16 
    Bladder cancer 10 8 5 8 5 7 20 8 
    Sarcoma 11 9 5 8 4 6 20 8 
    Melanoma 10 8 5 8 5 7 20 8 
    Other 9 7 5 8 7 10 21 8 
Extent of disease         
    Disease-free 2 2 2 3 0 0 4 2 
    Primary local disease 15 12 9 15 6 9 30 12 
    Local recurrence 6 5 4 6 3 4 13 5 
    Metastases 106 82 47 76 58 87 211 82 
Performance Status         
    0 25 19 5 8 9 13 39 15 
    1 63 49 23 37 29 43 115 45 
    2 29 22 26 42 24 36 79 31 
    3 11 9 8 13 5 7 24 9 
    4 1 1 0 0 0 0 1 0 
Treatment         
    Chemotherapy 97 75 47 76 53 79 197 76 
    Biological Therapy 27 21 13 21 13 19 53 21 
    Hormonotherapy 4 3 1 2 1 1 6 2 
    Observation 1 1 1 2 0 0 2 1 
         
   
 
 
  
 22 
Table 2 – Fixed Effects of the Mixed Effects Models for MCQ Subscales Change Score over Time 
 
   
Variables Estimate 
of Effect 
(EE) 
Standard 
Error 
95% CI P 
Communication       
    MCQ change scores       
        Intercept 35.37      
        Baseline Communication MCQ 0.55 0.05 0.45 - 0.65 <.0001 
    Time 0.01 0.01 -0.01 - 0.03 .30 
    Arm      .07 
        Intervention v Control 4.51 2.04 0.47 - 8.56 .03 
        Intervention v Attention Control 3.14 2.24 -1.29 - 7.57 .16 
    Doctor Gender (% females) -5.32 3.18 -11.63 - 0.98 .10 
    Doctor Seniority (% consultants) -2.67 3.24 -9.09 - 3.76 .41 
       
Coordination       
    MCQ change scores       
        Intercept 21.30      
        Baseline Continuity MCQ 0.51 0.05 0.41 - 0.61 <.0001 
    Time 0.02 0.01 0.00 - 0.05 .03 
    Arm      .42 
        Intervention v Control 0.20 2.44 -4.64 - 5.03 .94 
        Intervention v Attention Control 3.36 2.64 -1.87 - 8.60 .21 
    Doctor Gender (% females) -1.12 3.80 -8.65 - 6.41 .77 
    K-Index 21.54 4.67 12.28 - 30.80 <.0001 
       
Patient Preferences       
    MCQ change scores       
        Intercept 7.64      
        Baseline Preferences MCQ 0.76 0.05 0.66 - 0.86 <.0001 
    Time 0.01 0.01 -0.01 - 0.03 .39 
    Arm      .49 
        Intervention v Control 3.32 2.97 -2.57 - 9.20 .27 
        Intervention v Attention Control 0.09 3.23 -6.50 - 6.32 .98 
    Age 0.11 0.11 -0.10 - 0.32 .30 
       
   
 
  
 
 
 
